Objective: We conducted a first‐in‐human study to evaluate the bioactivity and safety of B7‐H3‐targeted chimeric antigen receptor (CAR) autologous T cells for treating recurrent anaplastic meningioma.Methods: Tumor tissues from a patient with recurrent anaplastic meningioma were evaluated for B7‐H3 expression. B7‐H3‐targeted CAR‐T cells were delivered into the intracranial tumor resection cavity using an Ommaya device at a maximum dose of 1.5 × 107 cells. Magnetic resonance imaging (MRI) screening and multiple serum indexes were regularly monitored. The patient received surgical intervention after three‐cycle infusions, allowing analysis for CAR‐T‐cell infiltration and target antigen expression in post‐CAR‐T therapy tumor tissues.Results: Immunochemical analysis demonstrated high and homogeneous B7‐H3 expression in tumor samples. MRI results indicated that the tumor near the delivery device was relatively stable compared with the rapid progression of tumors distant from the device. We found CAR‐T‐cell trafficking to regions of B7‐H3+ tumor tissues near the device, but not to tumor tissues distant from the device. Decreased B7‐H3 expression was observed near the region of CAR‐T‐cell infiltration after therapy. The intracavitary delivery of B7‐H3‐targeted CAR‐T cells was well‐tolerated and not associated with any toxic effects of grade 3 or higher.Conclusion: Our results suggested that although intracavitary administration of B7‐H3‐targeted CAR‐T cells was safe and resulted in local bioactivity, addressing antigen loss and CAR‐T‐cell trafficking may further enhance the applications of B7‐H3‐targeted CAR‐T‐cell therapy.
Bispecific antibodies (BsAb) and antibody-drug conjugates (ADC) have shown significant promise in cancer treatment, enhancing drug selectivity and therapeutic efficacy as demonstrated in multiple clinical studies. Bispecific antibody-drug conjugates (BsADC), which combine the targeting capabilities of BsAbs with the cytotoxic potential of ADCs, offer a novel approach to overcoming several challenges associated with ADCs, including limited internalization, off-target toxicity, and drug resistance. In this study, we identified solute carrier family 3 member 2 (SLC3A2) as a highly expressed protein in a variety of solid tumors, making it a promising therapeutic target. We developed a BsAb targeting SLC3A2 and PD-L1 and conjugated it to monomethyl auristatin E (MMAE) to create the SLC3A2/PD-L1 BsADC. The SLC3A2/PD-L1 BsAb effectively blocked PD-1 binding to PD-L1 and activated T cells while also facilitating lysosomal targeting and degradation of poorly internalized PD-L1 antibodies. The SLC3A2/PD-L1 BsADC demonstrated superior antitumor efficacy in PD-L1 low-expressing tumor cells compared with single-target ADCs in both in vitro studies and in multiple xenograft and immunocompetent mouse models. Overall, our engineered SLC3A2/PD-L1 BsADC exhibited enhanced internalization and improved tumor cell targeting, highlighting the potential of lysosome-targeting BsAbs in advancing ADC therapeutic strategies for solid tumors.
Supplementary Figure 4. LC-MS analysis and average DAR value of antibody-drug conjugates. A, LC-MS analysis of SLC3A2/PD-L1 BsADC. LC-MS, liquid chromatography-MS. The average DAR of SLC3A2/PD-L1 BsADC was 0.82. B, LC-MS analysis of SLC3A2 ADC. The average DAR of SLC3A2/PD-L1 BsADC was 1.63. C, LC-MS analysis of PD-L1 ADC. The average DAR of PD-L1 ADC was 0.93.
Supplementary Figure 5. Flow cytometry analysis for apoptosis. A, Flow cytometric analysis for cell apoptosis in SNU-899 cells. B, Flow cytometric analysis for cell apoptosis in H460 cells. C, Flow cytometric analysis for cel
Supplementary Figure 2. Specific targeting of anti-SLC3A2 19G4 mAb and anti-PD-L1 mAb. A, Sequencing results for HeLa SLC3A2KO cells using CRISPR/Cas9 technology. B, Flow cytometry analysis of 19G4 mAb specific binding to SLC3A2 in HeLa-WT and HeLa-SLC3A2KO cell lines. C, Flow cytometry analysis of 2217B3 mAb specific binding to PD-L1 in HeLa-WT and HeLa-PD-L1 cell lines. D, Flow cytometry analysis of 19G4 mAb binding to SLC7A5 and mouse SLC3A2. E, Flow cytometry analysis of 2217B3 mAb binding to PD-1 and mouse PD-L1.